ClinicalTrials.gg
Not yet recruitingNCT07527572GYNBAL-RBVUpdated Apr 14, 2026

Study to Evaluate Efficacy and Safety of Gyntima® Balance in Preventing Recurrences of Bacterial Vaginosis

A Phase 2/3 interventional study of Lactobacillus gasseri KABP®064 10e9 CFU/capsule and Placebo (maltodextrin) in Vaginosis, Bacterial, Bacterial Vaginosis and Bacterial Vaginosis (BV), sponsored by Kaneka Americas Holding Inc.. Not yet recruiting. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Kaneka Americas Holding Inc. (part of Kaneka Corporation) · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The vagina is a dynamic muscular organ whose health relies on a Lactobacillus-dominant microbiota that maintains low pH and protects against infections. Bacterial vaginosis (BV) is the most common vaginal imbalance in women of reproductive age, caused by depletion of protective Lactobacillus species and overgrowth of anaerobic bacteria such as Gardnerella vaginalis. BV affects an estimated 23-29 percentage of women globally (10-30 percentage in India) and is associated with discharge, odor, discomfort, and significant risks including recurrent disease, adverse reproductive outcomes, and increased susceptibility to STIs. Although antibiotics are effective for acute treatment, recurrence rates are high (50-60 percentage within 12 months), highlighting an unmet need for preventive strategies.

Probiotics, particularly Lactobacillus species, have emerged as promising options to restore vaginal microbiota balance and reduce BV recurrence. Lactobacillus gasseri is a natural vaginal commensal with antimicrobial activity against BV pathogens and the ability to lower vaginal pH. L. gasseri KABP®064 has demonstrated vaginal colonization after oral administration, good tolerability, and potential to promote vaginal health.

The present randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of oral L. gasseri KABP®064 in preventing BV recurrence over six months following standard antibiotic therapy. Outcomes include recurrence rates and timing, symptom severity, microbiological balance, inflammation markers, and patient-reported vaginal health, supporting a microbiome-focused, non-antibiotic approach to BV recurrence prevention.

02

Conditions studied

  • Vaginosis, Bacterial
  • Bacterial Vaginosis
  • Bacterial Vaginosis (BV)

Keywords

  • Recurrence
  • Microbiome
  • Metronidazole
  • Bacterial Vaginosis
03

In context

Vaginosis, Bacterial

240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.

This study's planned enrollment of 160 is above the median of 100 across 203 interventional studies indexed under Vaginosis, Bacterial.

Browse Vaginosis, Bacterial studies →

Lead sponsor

Kaneka Americas Holding Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females of ages 18-45 years (both values included) who are premenopausal.
  • History of recurrent BV (at least 3 episodes in the last 12 months with at least one of them documented in the last 6 months).
  • Positive Amsel's criteria (confirming active BV) determined by at least 3 out of the following 4 symptoms or signs:

    • Homogeneous, thin, yellowish-white/greyish white discharge that smoothly coats the vaginal walls.
    • Presence of the clue cells on microscopic examination (as assessed by wet mount test).
    • A fishy odor of vaginal discharge after adding 10% potassium hydroxide (KOH) solution to wet mount - also known as "whiff test".
    • Vaginal pH > 4.5
  • Imbalance in vaginal pH (pH > 4.5).
  • Participants with (BMI) 18.5-32.0 kg/m2.
  • Non-smokers.
  • Participants able to comply with and perform the procedures requested by the protocol (including dietary restrictions, consumption of study treatments, blood and urine sample collection procedures and study visit schedule).
  • Participants who are literate enough to understand the essence of study, are informed about the purpose of the study, and understand their rights.
  • Participants able to give written and willingness to participate in the study and comply with its procedures.

Exclusion criteria

Exclusion Criteria:

  • Participants currently taking and/or sexual hormones.
  • Pregnant or breastfeeding.
  • Menstrual period expected within the next 6 days of screening.
  • Irregular cycle ("irregular" (e.g., less than 21 or more than 35 days consistently, or cycle variability more than 4 days month-to-month).
  • Participants who have documented resistance to metronidazole.
  • Participants diagnosed with any vaginal or urinary tract infection other than BV.
  • Participants who have used other probiotics or antibiotics (vaginal, oral, parenteral) in the last 15 days.
  • Participants using other vaginal products with bacteriostatic or bactericide activity (such as lactic acid gels, herbal extracts, dequalinum chloride, etc.).
  • Participants with an intrauterine contraceptive device (IUCD/IUD) in situ at screening.
  • Participants who have undergone total hysterectomy or any other surgery involving the female reproductive system.
  • Women diagnosed with Sexually transmitted infections (STIs) or (HIV) infection.
  • Participants diagnosed with Polycystic ovary syndrome (PCOS) or other such diseases that further affect the hormonal homeostasis in women.
  • Presence of uncontrolled diabetes mellitus (Indicated by Fasting Blood Glucose (FBG) more than or equal to 126 mg/dL. Fasting is defined as no caloric intake for at least 8 hours).
  • Presence of uncontrolled hypertension (Defined as Systolic Blood Pressure (SBP) more than or equal to 140 mm Hg and/or Diastolic Blood Pressure (DBP) more than or equal to 90 mm Hg).
  • Untreated previously diagnosed thyroid disorders.
  • Participants who have a history of any significant neurological and psychiatric condition which may affect the participation and inference of the study's end points.
  • Participation in other clinical trials in last 3 months prior to screening.
  • Participants with substance abuse problems defined as:

    • High-risk drinking as defined by consumption of 4 or more alcohol containing beverages on any Day or 8 or more alcohol containing beverages per week for women.
  • Participants who have any of the following illness, i.e., Cardiovascular, endocrine system, immune system, respiratory system, hepatobiliary system, kidney and urinary system, neuropsychiatric, musculoskeletal, inflammatory, blood and tumors, chronic gastrointestinal diseases, etc.
  • Any condition that could, in the opinion of the Investigator, preclude the participant's ability to successfully and safely complete the study or that may confound study outcomes.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Probiotic

    Lactobacillus gasseri KABP064 in delayed-released (DR)-capsules. Strength: 1 x 10\^9 CFU/capsule

    Dietary Supplement: Lactobacillus gasseri KABP®064 10e9 CFU/capsule

  • Placebo comparator
    Placebo

    Placebo capsules filled with maltodextrine. Exact same appearance as active capsules.

    Dietary Supplement: Placebo (maltodextrin)

Interventions

  • Dietary supplementLactobacillus gasseri KABP®064 10e9 CFU/capsule

    Phase 1: 15 days, 1 capsule/day post-randomization. Phase 2: 10 days per month for \~6 months, starting 6th day of menstruation, 1 capsule/day.

  • Dietary supplementPlacebo (maltodextrin)

    Phase 1: 15 days, 1 capsule/day post-randomization. Phase 2: 10 days per month for \~6 months, starting 6th day of menstruation, 1 capsule/day.

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of Lactobacillus gasseri KABP®064 in preventing recurrence of BV infections, diagnosed using Amsel criteria, over a period of 6 months as compared to placebo.

    Amsel criteria (≥3 out of 4 positive)

    Time frame: Day 6 to Day 180

Secondary outcomes

  1. Analysis of BV recurrences diagnosed using Nugent score (≥ 7) (main secondary endpoint)

    Compared to Placebo

    Time frame: Day 6 to Day 180

  2. Analysis of BV recurrences diagnosed using both Amsel criteria (≥ 3 of 4 positive) and Nugent score (≥7)

    Compared to placebo

    Time frame: Day 6 to Day 180

  3. Time to first BV recurrence as per Amsel's criteria (≥3 of 4 positive) and/or Nugent Score (≥7)

    Compared to Placebo

    Time frame: Day 6 to Day 180

  4. Proportion of participants experiencing 2 or more, and 3 or more BV infections during the study period.

    Compared to Placebo

    Time frame: Day 6 to Day 180

  5. Percentage of patients receiving first-line or second-line SOC and duration (days).

    Compared to Placebo

    Time frame: Day 6 to Day 180

  6. Absolute difference in the duration of the SOC consumption (days).

    Compared to Placebo

    Time frame: Day 6 to Day 180

  7. Reducing the duration and severity of symptoms (itching, vaginal discharge, and odor) assessed by Visual Analogue Scale (VAS).

    Compared to Placebo

    Time frame: Day 0, Day 6, Day 22, Day 90, Day 180, and at recurrence visits (if patients have a BV recurrence during the study time frame, they will ask for a "recurrence visit" to assess medication and some study parameters).

  8. Percentage of patients with recovery of normal Nugent score (0-3).

    Compared to Placebo

    Time frame: Day 6 to Day 22

  9. Vaginal health by International Consultation on Incontinence Questionnaire - Vaginal symptoms (ICIQ-VS).

    Compared to Placebo

    Time frame: Day 0, Day 6, Day 22, Day 90 and Day 180

  10. Change in vaginal pH assessed by vaginal pH strip method.

    Compared to Placebo

    Time frame: Day 0, Day 6, Day 22, Day 90, Day 180, and at recurrence visits (if patients have a BV recurrence during the study time frame, they will ask for a "recurrence visit" to assess medication and some study parameters).

  11. Concentration of proinflammatory cytokines.

    Compared to Placebo

    Time frame: Day 0, Day 22

  12. Relative abundances of lactobacilli and common pathogens associated to BV assessed by using Next-Generation Sequencing (NGS).

    Compared to Placebo

    Time frame: Day 0, Day 6, Day 22, Day 90, Day 180

  13. Percentage of women with vaginal Community State Types (CSTs) associated to healthy vaginal microbiota.

    Compared to Placebo

    Time frame: Day 0, Day 6, Day 22, Day 90, Day 180

  14. Analysis of BV recurrences (including intermediate BV) as confirmed per Amsel criteria (≥ 3 of 4 positive) and Nugent score (score≥4) throughout the 6-month period.

    Compared to Placebo

    Time frame: Day 6 to Day 180

  15. Analysis of BV recurrences (including intermediate BV) as confirmed per Nugent score (score ≥4) throughout the 6-month period.

    Compared to Placebo

    Time frame: Day 6 to Day 180

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Apr 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Apr 14, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07527572
Collaborators
Vedic Lifesciences Pvt. Ltd., AB-Biotics
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Apr 14, 2026

Study contacts

Maria Rodriguez-Palmero, PhD
Contact
rodriguezpalmero@ab-biotics.com
+34 638679157
Núria Gispets Parés
Contact
gispets@ab-biotics.com
+34 607026612

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion